Edge Capital Group’s Biogen BIIB Stock Holding History

Edge Capital Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-4,022	Closed	-$951K	–	253
2019 Q1	$951K	Buy	+4,022	New	+$1.27M	0.09%	123

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Edge Capital Group's BIIB Position: Q2 2019 in Review

Edge Capital Group sold out of Biogen (BIIB) in Q2 2019, closing a stake of 4,022 shares — an estimated $951K sold.

Edge Capital Group first reported a position in BIIB in Q1 2019 and held it in 1 quarter. The position peaked at $951K in Q1 2019. 1,010 funds tracked by Wall St. Rank hold BIIB as of Q2 2019.

Edge Capital Group reported no remaining Biogen position as of Q2 2019 after selling out during the quarter.
Edge Capital Group sold 4,022 Biogen shares in Q2 2019, an estimated $951K.
Edge Capital Group first reported a position in Biogen in Q1 2019 and held it in 1 quarter.
Edge Capital Group's Biogen position peaked at $951K in Q1 2019.
1,010 funds tracked by Wall St. Rank held Biogen as of Q2 2019.

Based on Edge Capital Group's 13F filing for Q2 2019, filed 25 Jul 2019.